b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">30274984</PMID>\n        <DateCompleted>\n            <Year>2020</Year>\n            <Month>02</Month>\n            <Day>26</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>02</Month>\n            <Day>26</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Print">1078-0432</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>25</Volume>\n                    <Issue>1</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>01</Month>\n                        <Day>01</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>\n                <ISOAbbreviation>Clin. Cancer Res.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>253-265</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-18-1580</ELocationID>\n            <Abstract>\n                <AbstractText Label="PURPOSE">Resistance is an obstacle of glioma therapy. Despite targeted interventions, tumors harbor primary resistance or become resistant over short course of treatment. This study examined the mouse double minute 2 (MDM2) inhibitor RG7388 together with radiotherapy and analyzed strategies to overcome acquired MDM2 inhibitor resistance in glioblastoma.</AbstractText>\n                <AbstractText Label="EXPERIMENTAL DESIGN">Effects of RG7388 and radiotherapy were analyzed in p53 wild-type glioblastoma cell lines and glioma-initiating cells. RG7388 resistant cells were generated by increasing RG7388 doses over 3 months. Regulated pathways were investigated by microarray, qRT-PCR, and immunoblot analysis and specifically inhibited to evaluate rational salvage therapies at RG7388 resistance. Effects of RG7388 and trametinib treatment were challenged in an orthotopical mouse model with RG7388 resistant U87MG glioblastoma cells.</AbstractText>\n                <AbstractText Label="RESULTS">MDM2 inhibition required functional p53 and showed synergistic activity with radiotherapy in first-line treatment. Long-term exposure to RG7388 induced resistance by activation of the extracellular signal-regulated kinases 1/2 (ERK1/2)-insulin growth factor binding protein 1 (IGFBP1) signaling cascade, which was specifically overcome by ERK1/2 pathway inhibition with trametinib and knockdown of IGFBP1. Combining trametinib with continued RG7388 treatment enhanced antitumor effects at RG7388 resistance <i>in vitro</i> and <i>in vivo</i>.</AbstractText>\n                <AbstractText Label="CONCLUSIONS">These data provide a rationale for combining RG7388 and radiotherapy as first-line therapy with a specific relevance for tumors insensitive to alkylating standard chemotherapy and for the addition of trametinib to continued RG7388 treatment as salvage therapy after acquired resistance against RG7388 for clinical practice.</AbstractText>\n                <CopyrightInformation>\xc2\xa92018 American Association for Cancer Research.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Berberich</LastName>\n                    <ForeName>Anne</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Kessler</LastName>\n                    <ForeName>Tobias</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Thom\xc3\xa9</LastName>\n                    <ForeName>Carina M</ForeName>\n                    <Initials>CM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Pusch</LastName>\n                    <ForeName>Stefan</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Clinical Cooperation Unit Neuropathology, DKTK, DKFZ, Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hielscher</LastName>\n                    <ForeName>Thomas</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Biostatistics, DKFZ, Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Sahm</LastName>\n                    <ForeName>Felix</ForeName>\n                    <Initials>F</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Oezen</LastName>\n                    <ForeName>Iris</ForeName>\n                    <Initials>I</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, DKTK, DKFZ, Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Schmitt</LastName>\n                    <ForeName>Lara-Marie</ForeName>\n                    <Initials>LM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ciprut</LastName>\n                    <ForeName>Sara</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hucke</LastName>\n                    <ForeName>Nanina</ForeName>\n                    <Initials>N</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ruebmann</LastName>\n                    <ForeName>Petra</ForeName>\n                    <Initials>P</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Fischer</LastName>\n                    <ForeName>Manuel</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Lemke</LastName>\n                    <ForeName>Dieter</ForeName>\n                    <Initials>D</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Breckwoldt</LastName>\n                    <ForeName>Michael O</ForeName>\n                    <Initials>MO</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, DKTK, DKFZ, Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>von Deimling</LastName>\n                    <ForeName>Andreas</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Clinical Cooperation Unit Neuropathology, DKTK, DKFZ, Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Bendszus</LastName>\n                    <ForeName>Martin</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Platten</LastName>\n                    <ForeName>Michael</ForeName>\n                    <Initials>M</Initials>\n                    <Identifier Source="ORCID">0000-0002-4746-887X</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, DKTK, DKFZ, Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Wick</LastName>\n                    <ForeName>Wolfgang</ForeName>\n                    <Initials>W</Initials>\n                    <Identifier Source="ORCID">0000-0002-6171-634X</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. wolfgang.wick@med.uni-heidelberg.de.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2018</Year>\n                <Month>10</Month>\n                <Day>01</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Clin Cancer Res</MedlineTA>\n            <NlmUniqueID>9502500</NlmUniqueID>\n            <ISSNLinking>1078-0432</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="C032231">IGFBP1 protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D018970">Insulin-Like Growth Factor Binding Protein 1</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011728">Pyridones</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011744">Pyrimidinones</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011759">Pyrrolidines</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="C586849">RG7388</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="C495901">TP53 protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D062366">para-Aminobenzoates</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>33E86K87QN</RegistryNumber>\n                <NameOfSubstance UI="C560077">trametinib</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.3.2.27</RegistryNumber>\n                <NameOfSubstance UI="C497206">MDM2 protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.3.2.27</RegistryNumber>\n                <NameOfSubstance UI="D051736">Proto-Oncogene Proteins c-mdm2</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005909" MajorTopicYN="N">Glioblastoma</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n                <QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D064593" MajorTopicYN="N">Heterografts</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018970" MajorTopicYN="N">Insulin-Like Growth Factor Binding Protein 1</DescriptorName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D051736" MajorTopicYN="N">Proto-Oncogene Proteins c-mdm2</DescriptorName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011728" MajorTopicYN="N">Pyridones</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011744" MajorTopicYN="N">Pyrimidinones</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011759" MajorTopicYN="N">Pyrrolidines</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D062366" MajorTopicYN="N">para-Aminobenzoates</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2018</Year>\n                <Month>05</Month>\n                <Day>20</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2018</Year>\n                <Month>08</Month>\n                <Day>07</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2018</Year>\n                <Month>09</Month>\n                <Day>27</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2018</Year>\n                <Month>10</Month>\n                <Day>3</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>2</Month>\n                <Day>27</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2018</Year>\n                <Month>10</Month>\n                <Day>3</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30274984</ArticleId>\n            <ArticleId IdType="pii">1078-0432.CCR-18-1580</ArticleId>\n            <ArticleId IdType="doi">10.1158/1078-0432.CCR-18-1580</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'